This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Hong Kong Baptist University. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Shiqing Zhang: Innovator in Cancer Treatment
Introduction
Shiqing Zhang is a notable inventor based in Guangdong, China. He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on utilizing specific substrates as anti-cancer drugs, which has the potential to improve therapeutic outcomes for patients.
Latest Patents
Shiqing Zhang holds a patent for a method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs. The patent describes a method of treating cancer in a human patient by administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both. This method is particularly relevant for patients with cancer cells that exhibit elevated levels of these substrates, excluding 2-deoxy-D-glucose.
Career Highlights
Zhang is affiliated with Hong Kong Baptist University, where he conducts his research and develops his innovative ideas. His work has garnered attention for its potential impact on cancer therapies, showcasing his dedication to advancing medical science.
Collaborations
Shiqing Zhang collaborates with Stephen Chung, a fellow researcher, to further explore the applications of his patented methods in cancer treatment. Their partnership exemplifies the importance of teamwork in scientific research.
Conclusion
Shiqing Zhang's contributions to cancer treatment through his innovative patent highlight the potential of targeted therapies in improving patient outcomes. His work continues to inspire advancements in medical research and treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
